Biogen Inc (BIIB)

283.61
NASDAQ : Health Care
Prev Close 283.61
Day Low/High 0.00 / 0.00
52 Wk Low/High 223.02 / 333.65
Avg Volume 1.82M
Exchange NASDAQ
Shares Outstanding 217.57M
Market Cap 61.58B
EPS 15.40
P/E Ratio 19.23
Div & Yield N.A. (N.A)

Latest News

Forward Pharma Shares Jump on Biogen License Agreement

Forward Pharma Shares Jump on Biogen License Agreement

Biogen will pay Forward $1.25 billion.

Siemens Healthineers And Biogen Announce Agreement To Jointly Develop New MRI Tools For Multiple Sclerosis

Siemens Healthineers And Biogen Announce Agreement To Jointly Develop New MRI Tools For Multiple Sclerosis

Siemens Healthineers and Biogen have announced that the companies plan to jointly develop magnetic resonance imaging (MRI) applications with the intent of quantifying key markers of multiple sclerosis (MS) disease activity...

Biogen And Forward Pharma Agree To Enter Into Settlement And License Agreement

Biogen And Forward Pharma Agree To Enter Into Settlement And License Agreement

Biogen Inc. (NASDAQ: BIIB) today announced that it has agreed to enter into a settlement and license agreement with Forward Pharma, subject to the approval of Forward Pharma's shareholders and other customary...

Biotech Premarket Movers: SGMO, IPXL, PTLA

Biotech Premarket Movers: SGMO, IPXL, PTLA

Sangamo Therapeutics, Impax Laboratories and Portola Pharmaceutical are among the premarket movers in biotech.

Bioverativ Makes Splash in Trading Debut, Gaining 18% on Day One

Bioverativ Makes Splash in Trading Debut, Gaining 18% on Day One

Biogen spinoff Bioverativ proved healthy out of the gate, jumping from an open of $40 a share to a close of $47.35.

New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk Of Death Or Permanent Ventilation In Infantile-Onset Spinal Muscular Atrophy

New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk Of Death Or Permanent Ventilation In Infantile-Onset Spinal Muscular Atrophy

Biogen presented new data from the Phase 3 ENDEAR study of SPINRAZA™ (nusinersen), which demonstrated a statistically significant reduction in the risk of death or permanent ventilation in SPINRAZA-treated infants...

Biogen Spin-off Bioverativ Commences When-Issued Trading Of Common Stock

Biogen Spin-off Bioverativ Commences When-Issued Trading Of Common Stock

Biogen (NASDAQ:BIIB) today announced that it has been advised by NASDAQ that the common stock for Bioverativ, the spinoff of its global hemophilia business, begins trading today, Thursday, January 12, 2017, on a...

Biotech Investors 'Spooked' After Trump's Comments, JMP's King Says

Biotech Investors 'Spooked' After Trump's Comments, JMP's King Says

President-elect Donald Trump said the pharma industry was 'getting away with murder' during his first press conference as president-elect.

Analyst Favorites With Strong Buyback Activity: Biogen Ranks As a Top Pick

Analyst Favorites With Strong Buyback Activity: Biogen Ranks As a Top Pick

A study of analyst recommendations at the major brokerages shows that Biogen Inc is the #22 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity. To make that list, a stock must have repurchased at least 5% of its outstanding shares over the trailing twelve month period.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Warning: Sell-Side Analyst Call on Failed Ionis-Biogen Drug Causes Projectile Vomiting

Warning: Sell-Side Analyst Call on Failed Ionis-Biogen Drug Causes Projectile Vomiting

RBC Capital Markets biotech analyst Michael Yee takes a swivel-headed approach to fundamental research.

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.

Biotech Should Witness M&A's Return in 2017

Biotech Should Witness M&A's Return in 2017

Drug giants with money to spend and a friendlier regulatory environment should spur deals.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Biogen Could Suffer Near Term as the Chart Picture Erodes

Biogen Could Suffer Near Term as the Chart Picture Erodes

With weak chart patterns and a quantitative downgrade, longs should protect their positions.

Doug Kass' Top Pick for 2017: Short QQQ

Doug Kass' Top Pick for 2017: Short QQQ

Kass' trade of the year for 2017 is to short the PowerShares QQQ Trust ETF.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: HWBK, NBR, SGU, WEX, ZPIN Downgrades: BIIB, HMTV, LOGM, MTLS, NLSN, VSAT Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Dow Jones Loses Momentum on March to 20,000 While Nasdaq Hits Record

Dow Jones Loses Momentum on March to 20,000 While Nasdaq Hits Record

The Nasdaq reached a record high at Tuesday's close, but rising consumer confidence and positive housing-market data weren't enough to push the Dow Jones to 20,000.

Dow Retreats from 20,000 Milestone; Stocks Steady as Oil Closes Higher

Dow Retreats from 20,000 Milestone; Stocks Steady as Oil Closes Higher

The Dow's climb to 20,000 stalled Tuesday, but stocks remained somewhat higher. Consumer confidence is increasing, and housing prices are showing positive signs.

Biogen's Spinal Muscular Atrophy Drug Wins FDA Approval

Biogen's Spinal Muscular Atrophy Drug Wins FDA Approval

The U.S. Food and Drug Administration approved the biotech company's treatment for spinal muscular atrophy late Friday.

Dow Moves Toward 20,000; Stocks Higher as Consumer Confidence Rises

Dow Moves Toward 20,000; Stocks Higher as Consumer Confidence Rises

Stocks were slightly up on Tuesday as the Dow moves toward the 20,000 milestone and consumer confidence increases.

Biogen Scores FDA Approval for First Spinal Muscular Atrophy Drug

Biogen Scores FDA Approval for First Spinal Muscular Atrophy Drug

The biotech earlier this month enlisted Michael Vounatsos to replace George Scangos as chief executive.

My Top Pick for 2017: Short QQQ

My Top Pick for 2017: Short QQQ

Six reasons why the Nasdaq 100 ETF seems ready to pull back.

Biogen Announces Effectiveness Of Bioverativ Form 10 Registration Statement

Biogen Announces Effectiveness Of Bioverativ Form 10 Registration Statement

Biogen Inc. (NASDAQ: BIIB) today announced that the U.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

Biogen Announces That Bioverativ Will Host An Investor Day On January 6, 2017

Biogen Announces That Bioverativ Will Host An Investor Day On January 6, 2017

Biogen Inc. (NASDAQ: BIIB) announced today that Bioverativ, the planned spin-off of Biogen's hemophilia business, will host an Investor Day on January 6, 2017.